세계의 기관지 확장제 시장 : 약제 클래스별, 투여 경로별, 적응증별, 유통 채널별, 지역별(2025-2032년)
Global Bronchodilators Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography .
상품코드
:
1705950
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계의 기관지 확장제 시장은 2025년 228억 7,000만 달러로 추정되며, 2032년까지 296억 9,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 연평균 성장률(CAGR) 3.8%로 성장할 전망입니다.
| 보고 범위 |
보고서 세부정보 |
| 기준연도 |
2024년 |
2025년 시장 규모 |
228억 7,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간: 2025-2032년 CAGR: |
3.80% |
2032년 가치 예측 |
296억 9,000만 달러 |
그림. 기관지 확장제 세계 시장 점유율(%), 2025년 지역별
기관지 확장제는 폐기도를 넓혀 호흡을 편하게 하는 약입니다. 기관지 확장제는 갑작스런 호흡 곤란의 발작을 단기적으로 완화하는 데 사용되는 단시간 작용 유형과 천식 및 COPD의 숨결을 조절하고 천식의 부신 피질 스테로이드 약물 효과를 높이기 위해 정기적으로 사용되는 장시간 작용형이 있습니다. 콜린 억제제는 작동성 신경을 차단하여 기도를 넓힙니다. 기관지 확장제의 부작용은 특정 약물에 따라 다릅니다.
시장 역학:
세계의 기관지 확장제 시장의 성장을 견인하고 있는 것은 호흡기 질환에 걸리기 쉬운 고령자 인구 증가, 도시 및 농촌의 환경 오염 레벨 상승, 천식이나 COPD의 적절한 관리에 관한 의식 상승 등의 요인입니다. 그러나, 대체 치료 옵션의 이용 가능성, 기관지 확장제의 장기 사용에 수반되는 부작용, 블록버스터 약물의 특허 만료 등이 시장 성장을 억제할 것으로 예상되는 주요 요인의 일부입니다.
본 조사의 주요 특징
- 본 보고서는 세계 기관지확장제 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모 및 복합연간 성장률(CAGR)을 제공합니다.
- 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 이 보고서는 기관지 확장제 세계 시장에서 주요 기업 프로파일을 기업 하이라이트, 제품 포트폴리오, 주요 제품 하이라이트, 재무 실적, 전략 등의 매개 변수를 기반으로 게시합니다.
- 이 보고서로부터의 인사이트에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 발매, 유형 업, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
- 기관지 확장제 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등이 업계의 다양한 이해 관계자에 대응하고 있습니다.
- 이해관계자는 세계 기관지 확장제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 제품 승인 향상
- 엄격한 규제 환경
- 계발 캠페인 강화
- 주요 하이라이트
- 규제 시나리오
- 시장 동향
- 파이프라인 분석
- 제품 출시/승인
- PEST 분석
- PORTER 분석
- 역학
- 치료 알고리즘(환자 여정)
- 치료 옵션 분석
- 주요 시장 기업에 의한 신규 투자
- 가격 분석
- 질병 계발 프로그램
- 치료의 안전성과 효능의 분석
- 합병, 인수 및 제휴
제4장 세계 기관지 확장제 시장 - COVID-19 팬데믹의 영향
- COVID-19 역학
- 공급측과 수요측의 분석
- 경제에 미치는 영향
제5장 세계의 기관지 확장제 시장 : 약제 클래스별, 2020-2032년
- 베타 아드레날린성 기관지 확장제
- 크산틴 유도체
- 항콜린성 기관지 확장제
제6장 세계의 기관지 확장제 시장 : 투여 경로별, 2020-2032년
제7장 세계의 기관지 확장제 시장 : 적응증별, 2020-2032년
- 천식
- 만성 폐색성 폐질환(COPD)
- 기타(만성 기관지염 등)
제8장 세계의 기관지 확장제 시장 : 유통 채널별, 2020-2032년
제9장 세계의 기관지 확장제 시장 : 지역별, 2020-2032년
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제10장 경쟁 구도
- 기업 프로파일
- GSK plc.
- Mylan NV
- Mylan NV
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Novartis AG
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Cipla Inc.
- Sunovion Pharmaceuticals Inc.
- Sanofi
- Innoviva
제11장 섹션
JHS
영문 목차
Global Bronchodilators Market is estimated to be valued at USD 22.87 Bn in 2025 and is expected to reach USD 29.69 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.8% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 22.87 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
3.80% |
2032 Value Projection: |
USD 29.69 Bn |
Figure. Global Bronchodilators Market Share (%), By Region 2025
Bronchodilators are medications that help open up the airways in the lungs to allow for easier breathing. They work by relaxing and dilating the smooth muscles surrounding the bronchial tubes, thus reducing wheezing, coughing, shortness of breath and other symptoms associated with respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be either short-acting used as short-term relief from sudden, unexpected attacks of breathlessness or long-acting used regularly to help control breathlessness in asthma and COPD, and increase the effectiveness of corticosteroids in asthma. Anticholinergics (also known as antimuscarinics) are mainly used to treat COPD, but a few can also be used for asthma. Anticholinergics cause the airways to widen by blocking the cholinergic nerves. The side effects of bronchodilators can vary, depending on the specific medication. General side effects of bronchodilators include trembling, particularly in the hands, headache, muscle cramps, nausea and vomiting, diarrhea, etc.
Market Dynamics:
The global bronchodilators market growth is driven by factors such as the growing geriatric population which is more susceptible to respiratory diseases, increased environmental pollution levels in both urban and rural areas, and rising awareness about proper management of asthma and COPD. However, availability of alternative treatment options, side effects associated with long term use of bronchodilators, and patent expires of blockbuster drugs are some of the key factors expected to restrain market growth. Development of combination therapies that can deliver two or more drugs simultaneously is opening new opportunities for players in this market. Moreover, greater emphasis on preventive inhalation therapies for better management of respiratory symptoms will drive future demand.
Key features of the study:
- This report provides in-depth analysis of the global bronchodilators market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bronchodilators market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global bronchodilators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchodilators market
Detailed Segmentation:
- Global Bronchodilators Market, By Drug Class
- Beta-adrenergic Bronchodilators
- Xanthine Derivatives
- Anticholinergic Bronchodilators
- Global Bronchodilators Market, By Route of Administration
- Oral
- Nasal (inhalable)
- Injectable
- Global Bronchodilators Market, By Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others (Chronic bronchitis, etc.)
- Global Bronchodilators Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bronchodilators Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- GSK plc.
- AbbVie Inc.
- AstraZeneca
- Mylan N.V.
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Novartis AG
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Cipla Inc.
- Sunovion Pharmaceuticals Inc.
- Sanofi
- Innoviva
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Product Approval
- Stringent Regulatory Environment
- Increasing Awareness Campaigns
- Key Highlights
- Regulatory Scenario
- Market Trends
- Pipeline Analysis
- Product Launch/Approval
- PEST Analysis
- PORTER's Analysis
- Epidemiology
- Treatment Algorithm (Patient Journey)
- Treatment Option Analysis
- New Investments by Major Market Players
- Pricing Analysis
- Disease Awareness Programs
- Treatment Safety and Efficacy Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Bronchodilators Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Bronchodilators Market, By Drug Class, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Beta-adrenergic Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Xanthine Derivatives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Anticholinergic Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global Bronchodilators Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Nasal (inhalable)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Global Bronchodilators Market, By Indication, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Others (Chronic bronchitis, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
8. Global Bronchodilators Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 201s9-2032, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
9. Global Bronchodilators Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profile
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sunovion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- References
- Research Methodology
- About us
관련자료
